Clinical Trial Update: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pharmacokinetics and safety of a double-dose dolutegravir regimen when used with rifapentine for HIV-associated tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-associated Tuberculosis

Drugs mentioned

• Dolutegravir (dolutegravir)
• rifapentine (rifapentine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-associated Tuberculosis | Phase 2 | Status: COMPLETED